Application of metabolomics in Alzheimer's disease

Jordan Maximillian Wilkins, Eugenia Trushina

Research output: Contribution to journalReview articlepeer-review

63 Scopus citations


Progress toward the development of efficacious therapies for Alzheimer's disease (AD) is halted by a lack of understanding early underlying pathological mechanisms. Systems biology encompasses several techniques including genomics, epigenomics, transcriptomics, proteomics, and metabolomics. Metabolomics is the newest omics platform that offers great potential for the diagnosis and prognosis of neurodegenerative diseases as an individual's metabolome reflects alterations in genetic, transcript, and protein profiles and influences from the environment. Advancements in the field of metabolomics have demonstrated the complexity of dynamic changes associated with AD progression underscoring challenges with the development of efficacious therapeutic interventions. Defining systems-level alterations in AD could provide insights into disease mechanisms, reveal sex-specific changes, advance the development of biomarker panels, and aid in monitoring therapeutic efficacy, which should advance individualized medicine. Since metabolic pathways are largely conserved between species, metabolomics could improve the translation of preclinical research conducted in animal models of AD into humans. A summary of recent developments in the application of metabolomics to advance the AD field is provided below.

Original languageEnglish (US)
Article number719
JournalFrontiers in Neurology
Issue numberJAN
StatePublished - Jan 12 2018


  • Alzheimer's disease
  • Animal models of Alzheimer's disease
  • Biomarkers
  • Lipidomics
  • Metabolomics

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Application of metabolomics in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this